---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-178836"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2024-07-15T23:59:59+00:00"
generated_at: "2026-05-31T20:42:39.260642+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines guides 2024 net loss $560-600M; RMC-6236 shows 8.1-month PFS in 2L PDAC, Phase 3 planned

## Summary
- Net loss for FY2024 expected $560-600M, including $70-80M non-cash stock-based comp.
- Cash runway into 2027; current cash, equivalents, and marketable securities sufficient.
- RMC-6236 in 2L metastatic PDAC: median PFS 8.1 months (KRAS G12X); ORR 27% (20+ weeks treatment).
- Safety: 96% any-grade TRAEs, 22% Grade ≥3; 0% discontinuation; dose intensity 94%.
- Plans to initiate randomized Phase 3 RASolute 302 in 2H 2024 vs investigator's choice chemo.

## SEC filing metadata
- accession: 0001193125-24-178836
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2024-07-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312524178836/0001193125-24-178836-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312524178836/d869775d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-178836
- JSON: https://secwatch.observer/filing/0001193125-24-178836.json
- Plain text: https://secwatch.observer/filing/0001193125-24-178836.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.